.png){kind=icon}
.png){kind=icon}
Return
Targeting mitochondria in triple-negative breast cancer: Emerging therapeutic and drug development strategies
.png){kind=icon}
PRE
AI
Z
D
X
Q
J
L
DOI：10.1016/j.bbcan.2026.189591.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Dysregulation of mitochondria is closely implicated in the pathogenesis of TNBC. • Mitochondria modulate metabolic reprogramming, immune evasion, and programmed cell death in TNBC. • We summarize mitochondria-targeted therapeutic strategies for TNBC, including direct protein targeting, pathway regulation, mitochondrial modification, and combination regimens. • We review recent advances in TNBC clinical therapeutics from the perspective of mitochondria-related pathological mechanisms.
Keywords:
Mitochondria
Triple-negative breast cancer
Therapeutic strategies
Metabolic reprogramming
Immune evasion
Journal
B
IF:
0
Papers:
105
Citations:
0
Organization
Cited Papers